FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009422024> ?p ?o ?g. }

• W3009422024 endingPage "417.e8" @default.
• W3009422024 startingPage "417.e1" @default.
• W3009422024 abstract "Background The rising incidence rates of sexually transmitted infections in the United States highlight the need for concurrent treatment of patients and their sexual partners. Expedited partner therapy allows healthcare providers to offer antibiotic prescriptions or medications to an index patient for distribution to their sexual partner(s) without evaluating the partner. We hypothesized that there was a gap between expedited partner therapy policy at the state level and its downstream implementation by community pharmacists. Objective The objectives of our study were to evaluate pharmacists’ expedited partner therapy knowledge and practices in 41 expedited partner therapy–permissible US states, to determine whether there were differences in practice based on the length of time expedited partner therapy was permissible in the state and chlamydia incidence rates, and to measure the cost of expedited partner therapy treatment. Study Design A randomized cohort of pharmacists (n=335) was invited to complete a telephone interview from November 2017 through January 2018. Descriptive statistics were calculated and stratified by early, mid, and late expedited partner therapy–adopter status based on the year of the state’s expedited partner therapy enactment and the state’s chlamydia incidence rate. Fisher’s exact test and 1-way analyses of variance were used to compare measures across strata. Results We had 143 pharmacists (42.7%) agree to complete the survey. Among our respondents, 40.6% (n=58/143) indicated that they were aware of expedited partner therapy; 14.7% (n=21/143) reported that they had ever received an expedited partner therapy prescription, and 97% (n=139/143) reported that they would dispense an expedited partner therapy prescription if they received 1 in the future. These findings were stable across the 6 strata defined by early, mid, or late expedited partner therapy–adopter and high or low incidence rates of chlamydia status. Mean cost of azithromycin 1000 mg and cefixime 400 mg for treatment of chlamydia and gonorrhea was $22.17 (95% confidence interval, 20.29–24.05) and $30.46 (95% confidence interval, 28.65–32.26), respectively. Conclusion Fewer than one-half of the pharmacists were aware of expedited partner therapy. A small minority of pharmacists reported ever having received an expedited partner therapy prescription, regardless of the length of time expedited partner therapy had been legal in their states and the incidence of chlamydia. However, almost all pharmacists reported that they would dispense an expedited partner therapy prescription if they received 1. Additionally, costs were high for expedited partner therapy for self-pay patients. These data suggest that there are opportunities to increase expedited partner therapy utilization by healthcare providers, patients, and pharmacists. The rising incidence rates of sexually transmitted infections in the United States highlight the need for concurrent treatment of patients and their sexual partners. Expedited partner therapy allows healthcare providers to offer antibiotic prescriptions or medications to an index patient for distribution to their sexual partner(s) without evaluating the partner. We hypothesized that there was a gap between expedited partner therapy policy at the state level and its downstream implementation by community pharmacists. The objectives of our study were to evaluate pharmacists’ expedited partner therapy knowledge and practices in 41 expedited partner therapy–permissible US states, to determine whether there were differences in practice based on the length of time expedited partner therapy was permissible in the state and chlamydia incidence rates, and to measure the cost of expedited partner therapy treatment. A randomized cohort of pharmacists (n=335) was invited to complete a telephone interview from November 2017 through January 2018. Descriptive statistics were calculated and stratified by early, mid, and late expedited partner therapy–adopter status based on the year of the state’s expedited partner therapy enactment and the state’s chlamydia incidence rate. Fisher’s exact test and 1-way analyses of variance were used to compare measures across strata. We had 143 pharmacists (42.7%) agree to complete the survey. Among our respondents, 40.6% (n=58/143) indicated that they were aware of expedited partner therapy; 14.7% (n=21/143) reported that they had ever received an expedited partner therapy prescription, and 97% (n=139/143) reported that they would dispense an expedited partner therapy prescription if they received 1 in the future. These findings were stable across the 6 strata defined by early, mid, or late expedited partner therapy–adopter and high or low incidence rates of chlamydia status. Mean cost of azithromycin 1000 mg and cefixime 400 mg for treatment of chlamydia and gonorrhea was $22.17 (95% confidence interval, 20.29–24.05) and $30.46 (95% confidence interval, 28.65–32.26), respectively. Fewer than one-half of the pharmacists were aware of expedited partner therapy. A small minority of pharmacists reported ever having received an expedited partner therapy prescription, regardless of the length of time expedited partner therapy had been legal in their states and the incidence of chlamydia. However, almost all pharmacists reported that they would dispense an expedited partner therapy prescription if they received 1. Additionally, costs were high for expedited partner therapy for self-pay patients. These data suggest that there are opportunities to increase expedited partner therapy utilization by healthcare providers, patients, and pharmacists." @default.
• W3009422024 created "2020-03-13" @default.
• W3009422024 creator A5025963087 @default.
• W3009422024 creator A5052995907 @default.
• W3009422024 creator A5055838957 @default.
• W3009422024 creator A5056109491 @default.
• W3009422024 creator A5086988987 @default.
• W3009422024 creator A5089637430 @default.
• W3009422024 date "2020-09-01" @default.
• W3009422024 modified "2023-09-26" @default.
• W3009422024 title "Breakdown in the expedited partner therapy treatment cascade: from reproductive healthcare provider to the pharmacist" @default.
• W3009422024 cites W1652810469 @default.
• W3009422024 cites W1981876801 @default.
• W3009422024 cites W1994425575 @default.
• W3009422024 cites W2031767708 @default.
• W3009422024 cites W2044144417 @default.
• W3009422024 cites W2047697023 @default.
• W3009422024 cites W2059224434 @default.
• W3009422024 cites W2072744471 @default.
• W3009422024 cites W2128708588 @default.
• W3009422024 cites W2169663345 @default.
• W3009422024 cites W2531291060 @default.
• W3009422024 cites W2611837633 @default.
• W3009422024 cites W2621247255 @default.
• W3009422024 cites W2751308234 @default.
• W3009422024 cites W2765323251 @default.
• W3009422024 cites W2789545364 @default.
• W3009422024 cites W2791254626 @default.
• W3009422024 cites W2807950103 @default.
• W3009422024 cites W2891801678 @default.
• W3009422024 doi "https://doi.org/10.1016/j.ajog.2020.02.038" @default.
• W3009422024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32135143" @default.
• W3009422024 hasPublicationYear "2020" @default.
• W3009422024 type Work @default.
• W3009422024 sameAs 3009422024 @default.
• W3009422024 citedByCount "8" @default.
• W3009422024 countsByYear W30094220242020 @default.
• W3009422024 countsByYear W30094220242021 @default.
• W3009422024 countsByYear W30094220242022 @default.
• W3009422024 crossrefType "journal-article" @default.
• W3009422024 hasAuthorship W3009422024A5025963087 @default.
• W3009422024 hasAuthorship W3009422024A5052995907 @default.
• W3009422024 hasAuthorship W3009422024A5055838957 @default.
• W3009422024 hasAuthorship W3009422024A5056109491 @default.
• W3009422024 hasAuthorship W3009422024A5086988987 @default.
• W3009422024 hasAuthorship W3009422024A5089637430 @default.
• W3009422024 hasConcept C104863432 @default.
• W3009422024 hasConcept C105795698 @default.
• W3009422024 hasConcept C120665830 @default.
• W3009422024 hasConcept C121332964 @default.
• W3009422024 hasConcept C159110408 @default.
• W3009422024 hasConcept C160735492 @default.
• W3009422024 hasConcept C162324750 @default.
• W3009422024 hasConcept C194828623 @default.
• W3009422024 hasConcept C203014093 @default.
• W3009422024 hasConcept C2426938 @default.
• W3009422024 hasConcept C2776135927 @default.
• W3009422024 hasConcept C2779457091 @default.
• W3009422024 hasConcept C2780122209 @default.
• W3009422024 hasConcept C33923547 @default.
• W3009422024 hasConcept C39896193 @default.
• W3009422024 hasConcept C50522688 @default.
• W3009422024 hasConcept C512399662 @default.
• W3009422024 hasConcept C61511704 @default.
• W3009422024 hasConcept C71924100 @default.
• W3009422024 hasConceptScore W3009422024C104863432 @default.
• W3009422024 hasConceptScore W3009422024C105795698 @default.
• W3009422024 hasConceptScore W3009422024C120665830 @default.
• W3009422024 hasConceptScore W3009422024C121332964 @default.
• W3009422024 hasConceptScore W3009422024C159110408 @default.
• W3009422024 hasConceptScore W3009422024C160735492 @default.
• W3009422024 hasConceptScore W3009422024C162324750 @default.
• W3009422024 hasConceptScore W3009422024C194828623 @default.
• W3009422024 hasConceptScore W3009422024C203014093 @default.
• W3009422024 hasConceptScore W3009422024C2426938 @default.
• W3009422024 hasConceptScore W3009422024C2776135927 @default.
• W3009422024 hasConceptScore W3009422024C2779457091 @default.
• W3009422024 hasConceptScore W3009422024C2780122209 @default.
• W3009422024 hasConceptScore W3009422024C33923547 @default.
• W3009422024 hasConceptScore W3009422024C39896193 @default.
• W3009422024 hasConceptScore W3009422024C50522688 @default.
• W3009422024 hasConceptScore W3009422024C512399662 @default.
• W3009422024 hasConceptScore W3009422024C61511704 @default.
• W3009422024 hasConceptScore W3009422024C71924100 @default.
• W3009422024 hasIssue "3" @default.
• W3009422024 hasLocation W30094220241 @default.
• W3009422024 hasLocation W30094220242 @default.
• W3009422024 hasOpenAccess W3009422024 @default.
• W3009422024 hasPrimaryLocation W30094220241 @default.
• W3009422024 hasRelatedWork W1731384364 @default.
• W3009422024 hasRelatedWork W1784093982 @default.
• W3009422024 hasRelatedWork W1984922927 @default.
• W3009422024 hasRelatedWork W2000043229 @default.
• W3009422024 hasRelatedWork W2041884123 @default.
• W3009422024 hasRelatedWork W2552583352 @default.
• W3009422024 hasRelatedWork W3137819944 @default.
• W3009422024 hasRelatedWork W3188803873 @default.
• W3009422024 hasRelatedWork W3204073435 @default.

• next